Analyzing an investigational ophthalmic solution for treating presbyopia-related symptoms

Michael R. Robinson, MD, Allergan, discusses the results from a study analyzing an investigational ophthalmic solution for treatment of symptoms associated with presbyopia presented during the virtual AAO 2020 meeting.

Michael R. Robinson, MD, vice president, Global Therapeutic Area Head, Ophthalmology at Allergan, an AbbVie company, discusses the results from a presentation titled, "Two Phase b Study Results for the Development of a Proprietary Formulation for the Treatment of Presbyopia," presented during the virtual AAO 2020 meeting.

See more AAO coverage here

Related Videos
TENAYA, LUCERNE year 2 data reveals promising results for faricimab
How to diagnose geographic atrophy earlier
World Sight Day 2022: Eye care professionals share what global vision means to them
© 2023 MJH Life Sciences

All rights reserved.